Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: Oncogenic Tumor Board in Advanced NSCLC: How Do You Strategize Treatment Planning for EGFR-Mutated and ALK-Rearranged Patients?

ASCO: Oncogenic Tumor Board in Advanced NSCLC: How Do You Strategize Treatment Planning for EGFR-Mutated and ALK-Rearranged Patients?


Sunday, June 2, 2019

Dinner and Registration: 6:30 PM – 7:00 PM
Program: 7:00 PM - 9:00 PM

Location
Hilton Chicago
International Ballroom North (Second Level)
720 S Michigan Ave
Chicago, IL 60605

Overview

This live CME program presented at the American Society of Clinical Oncology Annual Meeting describes current and emerging strategies for the management of patients with EGFR-mutated and ALK-mutated forms of non–small cell lung cancer (NSCLC). Appropriate strategies for identification of EGFR and ALK mutations will be explored in this program, including current strategies for the most effective use of targeted therapies. Appropriate sequencing of agents, including in patients with the ALK mutation variant T790M, will be discussed, as well as best practices for management of patients who develop resistance to initial therapy. Strategies for patient selection based on phenotypic characteristics, clinical trials for combination therapy of tyrosine kinase inhibitors and immunotherapy, the relative efficacy of agents in patients with brain metastases, and the latest updates from clinical trials in NSCLC will be examined in detail through both didactic presentations and case-based, tumor board multi-faculty discussions.

Benefits of Attending

  • Update and confirm your practice with best practices in pathologic review of patients for ALK mutations, EGFR mutations, and other mutations using the latest and most accurate diagnostic techniques
  • Learn the best approaches for management of patients with EGFR and ALK mutations, including appropriate sequencing of therapies in patients who develop resistance mutations across lines of treatment
  • Through case-based learning and in-depth review of clinical trial results, learn the best practices for patients with actionable EGFR and ALK mutations who also have brain metastases
  • See how top experts in the field develop appropriate treatment plans for a variety of patients using a collaborative tumor board format that incorporates data from the latest trials and current clinical best practices

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Educational Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe appropriate testing strategies that impact the development of optimal NSCLC treatment plans in the first line and beyond
  • Describe newly approved and emerging targeted therapeutic strategies that can be administered in the clinical management of NSCLC with EGFR or ALK molecular aberrations
  • Apply sequential targeted approaches to treat NSCLC with EGFR or ALK molecular aberrations
  • Develop and implement strategies to monitor responses and mitigate treatment-related toxicities

Program Chair

David R. GandaraDavid R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Click to see all our ASCO programs!

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.    

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By